<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082000</url>
  </required_header>
  <id_info>
    <org_study_id>BOL-P-4</org_study_id>
    <nct_id>NCT04082000</nct_id>
  </id_info>
  <brief_title>Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy</brief_title>
  <official_title>A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath of Life International Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath of Life International Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2a Study Examining the Safety
      and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2a, two-center, randomized, double-blind, placebo-controlled study in which subjects
      will be randomized to receive either BOL-DP-o-04 or placebo in addition to Standart of Care.
      The study evaluates the effect of BOL-DP-o-04 for Diabetic Neuropathy. The study includes a
      screening period up to three weeks followed by a 12-week treatment period
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple (Participant, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with &gt;30% reduction in neuropathic pain</measure>
    <time_frame>Baseline to week 15</time_frame>
    <description>Assessed by the DN4 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>First treatment upto 15 weeks</time_frame>
    <description>All AEs will be recorded, whether considered minor or serious, drug-related or not</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of QoL from baseline</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Assessed by Diabetes Quality of Life Questionnaire (DQOL) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Assessed by HbA1c blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c &lt; 7%</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Assessed by HbA1c blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of blood pressure</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>weight measured by Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep disturbance</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Assessed by the sleep disturbance (PSQI) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>BOL-DP-o-04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-DP-o-04</intervention_name>
    <description>BOL-DP-o-04</description>
    <arm_group_label>BOL-DP-o-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects with Type 1 or Type 2 diabetes

          2. Diabetes duration of at least 1 year

          3. HbA1c 6%-12%

          4. 18 years of age or older

          5. Diabetic neuropathy for at least 6 months

          6. Failed or uncontrolled treatment of diabetic neuropathy following treatment with at
             least two drugs from the following drug list (Pregabalin / Dulexatine/ Amitriptyline /
             gabapentin /carbamazepine) for a duration of at least three months for each drug

          7. Score equal or above 50% in DN4 questionnaire

        Exclusion Criteria:

          1. Neuropathic pain other than diabetic

          2. A score of less than 50% on DN4 questionnaire

          3. History of substance abuse (alcohol / illegal drugs)

          4. History of cannabis or cannabis product usage in the last three months

          5. Any decompensated chronic disease

          6. Pregnancy/lactation

          7. Participant in other clinical trial during the last 30 days

          8. A current of history of cancer during the last year

          9. Any mental/psychiatric illness in first-degree relative in a young patient &lt;30 years
             old.

         10. Any food allergy

         11. History of amputation

         12. Any disorder which in the investigator's opinion might jeopardize the subject's safety
             or compliance with the protocol

         13. Patients with known allergy to one or more of the study drug components.

         14. Patient with uncontrolled congestive heart failure

         15. Subjects who get the following medications: opiates, Primidone, Phenobarbitol,
             carbamazepine, Rifampicin, Rifabutin, Troglitazone, and Hypericum perforatum

         16. Patients with psychotic state in the past or anxiety disorder

         17. Subject with a history of addiction or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julio Wainstein, M.D.</last_name>
    <phone>+972506296940</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boaz Hirshberg, M.D.</last_name>
    <email>boaz.hirshberg@bolpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>HÌ±olon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Wainstein, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 31, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

